|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3800 - 0.4027|
|52 Week Range||0.2161 - 1.6000|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The update reflects the Company's revenue generation activities and continued position as the only company with medical cannabis sales in Colombia."Through our branded clinics in Colombia, third-party pharmacies, educations programs, and expanded global markets we are fully focused on revenue generation and meeting patient needs in Latin America and globally.
TORONTO, July 23, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today that it has received import licenses and all necessary authorizations from the Directorate General of Drug Supplies and Drugs (DIGEMID) for the import and commercialization of full spectrum, high-CBD medical cannabis products from Khiron Colombia into Peru.
TORONTO, July 21, 2020 -- Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), announces that MNP LLP (the “Former.